Table 4 Comparison of pretreatment and follow-up CT features
From: Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
Parameters | Total patients (n = 41) | hUC-MSC (N = 12) | Control (N = 29) | P value |
|---|---|---|---|---|
Pretreatment | ||||
 CT score | 18.00 (15.00, 20.00) | 18.50 (16.25, 20.75) | 16.00 (15.00, 20.00) | 0.1946 |
 Number of lobes involved | 4 (4, 5) | 4 (4, 5) | 4 (3.5, 5) | 0.5826 |
 GGO | 41 (100%) | 12 (100%) | 29 (100%) | 1.0000 |
 Linear opacities | 36 (87.80%) | 10 (83.33%) | 26 (89.66%) | 0.6197 |
 Consolidation | 35 (85.37%) | 11 (91.67%) | 25 (86.21%) | 1.0000 |
 Interlobular septal thickening | 35 (85.37%) | 10 (83.33%) | 25 (86.21%) | 1.0000 |
 Crazy-paving pattern | 22 (53.65%) | 7 (58.33%) | 15 (51.72%) | 0.7437 |
 Subpleural curvilinear line | 16 (39.02%) | 6 (50.00%) | 10 (34.48%) | 0.7300 |
 Bronchial wall thickening | 27 (65.85%) | 8 (66.67%) | 19 (65.52%) | 1.0000 |
 Lymph node enlargement | 20 (48.78%) | 5 (41.67%) | 15 (51.72%) | 0.7337 |
 Pleural effusion | 5 (12.20%) | 2 (16.67%) | 3 (10.34%) | 0.6197 |
2 weeks after treatment§ | ||||
 CT score | 9.00 (8.00, 10.50) | 8.50 (7.25, 9.00) | 10.00 (8.50, 12.50) | 0.017* |
 Number of lobes involved | 3 (2, 3) | 2 (2, 2) | 3 (2, 3) | < 0.001*** |
 GGO | 23 (58.97%) | 4 (33.33%) | 19 (70.37%) | 0.0407* |
 Linear opacities | 26 (66.67%) | 5 (41.67%) | 21 (77.78%) | 0.0624 |
 Consolidation | 27 (69.23%) | 4 (33.33%) | 20 (74.07%) | 0.0306* |
 Interlobular septal thickening | 25 (64.10%) | 5 (41.67%) | 20 (74.07%) | 0.0636 |
 Crazy-paving pattern | 16 (41.03%) | 3 (25.00%) | 13 (48.15%) | 0.2913 |
 Subpleural curvilinear line | 12 (30.77%) | 3 (25.00%) | 9 (33.33%) | 0.7190 |
 Bronchial wall thickening | 22 (56.41%) | 4 (33.33%) | 18 (66.67%) | 0.0820 |
 Lymph node enlargement | 16 (41.03%) | 3 (25.00%) | 13 (48.15%) | 0.2913 |
 Pleural effusion | 3 (7.69%) | 1 (8.33%) | 2 (7.41%) | 1.0000 |